California is currently home to 5613 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms
Recruiting
Patients harboring dolichoectactic vertebrobasilar (DVB) aneurysms are at risk of suffering SAH, ischemic stroke, and/or brainstem compression and many patients are not offered invasive treatment due to the futility of existing surgical methods. Consequently, there is demand for development of medical therapy for DVB aneurysms
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: UCSF Medical Center, San Francisco, California
Conditions: Aneurysm, Stroke, Vasculitis, Tumor Necrosis Factor-alpha
A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease
Recruiting
A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease study is being conducted at the University of California San Francisco and 30 other sites around the United States who are part of the CCFA Clinical Alliance. The aim of this study is to determine the effect of medication use and disease activity on the outcome of pregnancy among women with IBD up to 18 years from birth.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
07/02/2025
Locations: Please Contact Jessica Lim For Further Information Regarding Other Sites' Locations, San Francisco, California
Conditions: Inflammatory Bowel Disease
SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era
Recruiting
SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infection, progression, non-progression, response to treatment, control of HIV-1 virus, and evolution of drug resistance.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: San Francisco General Hospital, San Francisco, California
Conditions: HIV Infections
Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease
Recruiting
This is a study to measure liver recovery in patients with recent alcohol-associated liver injury by assessing liver function and physiology using HepQuant DuO. The HepQuant DuO Test is a blood-based test that involves a drink of a natural compound, cholate, and 2 blood samples at 20 and 60 minutes. The study team is collecting clinical and laboratory data to better monitor and treat patients who have been affected by alcohol-associated liver disease. The study has 4 visits at an outpatient clin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Stanford University Dept. of Medicine -Gastroenterology & Hepatology, Redwood City, California
Conditions: Alcoholic Hepatitis, Alcohol-related Liver Disease
A Study Assessing KB803 Compared to Matching Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa
Recruiting
KB803-EYE-01 is a Phase 3 double-blind, intra-patient crossover study, to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).
Gender:
ALL
Ages:
6 months and above
Trial Updated:
07/01/2025
Locations: Mission Dermatology Center, Rancho Santa Margarita, California
Conditions: Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
A Study of LY3981314 in Healthy Participants
Recruiting
The main purpose of this study is to investigate the safety of LY3981314 when administered subcutaneously (SC) (under the skin), and how it's processed in the body. The study will last approximately 25 weeks, excluding a screening period with an optional extension to approximately 49 weeks for qualifying participants.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/01/2025
Locations: CenExel ACT, Anaheim, California
Conditions: Healthy
Study for AZD4360 in Participants With Advanced Solid Tumours
Recruiting
The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Santa Monica, California
Conditions: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Recruiting
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/01/2025
Locations: Wolverine Clinical Trials, Santa Ana, California
Conditions: Type 2 Diabetes
Description of Patients With Type 1 Diabetes Treated With Teplizumab
Recruiting
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic β cells. T1D pathogenesis progresses through several stages: Stage 1 T1D includes the presence of β cell autoimmunity and thus presence of islet autoantibodies, without the presence of dysglycemia and symptoms. Stage 2 T1D includes the presence of islet autoantibodies and dysglycemia, also with no symptoms. Stage 3 T1D includes presence of islet autoantibodies, overt hyperglycemia, and symptoms... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/01/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Type 1 Diabetes
A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer
Recruiting
This is an open-label, non-randomized, exploratory platform protocol designed to assess the safety and antitumor activity of epigenetic therapies in participants with localized prostate cancer who are undergoing radical prostatectomy. The epigenetic therapy is intended to increase the sensitivity of the underlying tumor to the patient's immune system. The platform study will evaluate safety, biomarkers, and clinical activity of an epigenetic therapy. The particular details relevant to each modul... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Cedars-Sinai Cancer at SOCC, Los Angeles, California
Conditions: High-risk Prostate Cancer
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
Recruiting
The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers. The study is placebo-controlled with two treatment arms.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/01/2025
Locations: Vanda Investigational Site, Los Angeles, California
Conditions: Obesity
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Los Angeles, California
Conditions: Metastatic Colorectal Cancer